|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.190 - 0.200|
|52 Week Range||0.150 - 0.350|
|PE Ratio (TTM)||-1.03|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Research Desk Line-up: China Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
HAIKOU, China, Sept. 12, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (the "Company") today announced receipt of notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") that the Company is not in compliance with certain NYSE American continued listing standards or the Listing Standards. The Deficiency Letter indicated that the Company's securities have been selling for a low price per share for a substantial period of time and, most recently, the average price of the Company's common stock had been below $0.20 on a 30-day average as of September 5, 2017. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company's continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the staff determined to be until March 6, 2018.
Categories: Yahoo FinanceGet free summary analysis China Pharma Holdings, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of China Pharma Holdings, Inc. – Mylan N.V., Teva Pharmaceutical Industries Limited Sponsored ADR, Dr. Reddy’s Laboratories Ltd. Sponsored ADR, China Biologic Products Holdings, Inc., Novartis AG Sponsored ... Read more (Read more...)